PT  - JOURNAL ARTICLE
AU  - van Kempen, Evelien B.
AU  - Bruijning-Verhagen, Patricia C.J.
AU  - Borensztajn, Dorine
AU  - Vermont, Clementien L.
AU  - Quaak, Marjolijn S.W.
AU  - Janson, Jo-Anne
AU  - Maat, Ianthe
AU  - Stol, Kim
AU  - Vlaminckx, Bart J.M.
AU  - Wieringa, Jantien W.
AU  - van Sorge, Nina M.
AU  - Boeddha, Navin P.
AU  - van Veen, Mirjam
TI  - INCREASE IN INVASIVE GROUP A STREPTOCOCCAL INFECTIONS IN CHILDREN IN THE NETHERLANDS, A SURVEY AMONG 7 HOSPITALS IN 2022
AID  - 10.1101/2022.12.13.22283399
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.13.22283399
4099  - http://medrxiv.org/content/early/2022/12/13/2022.12.13.22283399.short
4100  - http://medrxiv.org/content/early/2022/12/13/2022.12.13.22283399.full
AB  - Based on a survey sent to seven Dutch hospitals, we observed an substantial increase in invasive group A streptococcal infections in children in the Netherlands, comparing the pre-COVID-19 pandemic cohort of 2018-2019 to 2021-2022. The most affected age group were children between 0-5 years. Main diagnosis was pneumonia with empyema. Necrotizing fasciitis and streptococcal toxic shock syndrome were also reported in 11% and 7% respectively. A significant number was admitted to the Paediatric Intensive Care Unit. Vigilance is needed.Competing Interest StatementNMvS declares royalties related to a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). All other authors report no conflicts of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Medical research Ethics Committees United the Netherlands (MEC-U) gave ethical approval for this work This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The ethical review board (MEC-U, reference number W18.201) deemed that the Medical Research Involving Human Subjects Act (WMO) does not apply to our studyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset used and analysed supporting the conclusions of this manuscript are available from the corresponding author on reasonable request.